Generation of CD8⁺ T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy

References

• Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong V, Morris E, Stauss HJ. Exploiting T cell receptor genes for cancer immunotherapy. Clin Exp Immunol 2005; 139:167-72; PMID:15654813; http://dx.doi.org/10.1111/j.1365-2249.2005.02715.x.
   PubMed Web of Science ®Google Scholar
• Bolhuis RL, Willemsen RA, Gratama JW. Clinical applications of redirected cytotoxicity. In Sitkovsky MV, Henkart PA, editors. Cytotoxic cells. Philadelphia: Lippincott, Williams & Wilkins; 2000; 423-40.
   Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514.
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191.
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, Abken H, Schumacher TN, ATTACK Consortium. Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther 2010; 21:665-72; PMID:20408760; http://dx.doi.org/10.1089/hum.2010.086.
   PubMed Web of Science ®Google Scholar
• Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2:512-9; PMID:12094225; http://dx.doi.org/10.1038/nri841.
   PubMed Web of Science ®Google Scholar
• Schaft N, Dorrie J, Muller I, Beck V, Baumann S, Schunder T, Kampgen E, Schuler G. A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother 2006; 55:1132-41; PMID:16344988; http://dx.doi.org/10.1007/s00262-005-0098-2.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 2006; 13:151-9; PMID:16140584; http://dx.doi.org/10.1016/j.ymthe.2005.07.688.
   PubMed Web of Science ®Google Scholar
• Krug C, Wiesinger M, Abken H, Schuler-Thurner B, Schuler G, Dorrie J, Schaft N. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immunother 2014; 63:999-1008; PMID:24938475; http://dx.doi.org/10.1007/s00262-014-1572-5.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991.
   PubMed Web of Science ®Google Scholar
• Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wolfel C, Huber C, Wolfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005; 102:16013-8; PMID:16247014; http://dx.doi.org/10.1073/pnas.0500090102.
   PubMed Web of Science ®Google Scholar
• Hadrup S, Donia M, thor SP. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron 2013; 6:123-33; PMID:23242673; http://dx.doi.org/10.1007/s12307-012-0127-6.
   PubMedGoogle Scholar
• Restifo NP, Wunderlich JR. Principles of tumor immunity: biology of cellular immune responses. In DeVita VT, Hellman S, Rosenberg SA, editors. Biologic Therapy of Cancer. Philadelphia: Lippincott Co 1996; 3-21.
   Google Scholar
• Hofmann C, Hofflin S, Huckelhoven A, Bergmann S, Harrer E, Schuler G, Dorrie J, Schaft N, Harrer T. Human T cells expressing two additional receptors (TETARs) specific for HIV-1 recognize both epitopes. Blood 2011; 118:5174-7; PMID:21926350; http://dx.doi.org/10.1182/blood-2011-04-347005.
   PubMed Web of Science ®Google Scholar
• Bialer G, Horovitz-Fried M, Ya'acobi S, Morgan RA, Cohen CJ. Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol 2010; 184:6232-41; PMID:20427762; http://dx.doi.org/10.4049/jimmunol.0902047.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006; 66:8878-86; PMID:16951205; http://dx.doi.org/10.1158/0008-5472.CAN-06-1450.
   PubMed Web of Science ®Google Scholar
• Sommermeyer D, Uckert W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol 2010; 184:6223-31; PMID:20483785; http://dx.doi.org/10.4049/jimmunol.0902055.
   PubMed Web of Science ®Google Scholar
• Tanic N, Brkic G, Dimitrijevic B, Dedovic-Tanic N, Gefen N, Benharroch D, Gopas J. Identification of differentially expressed mRNA transcripts in drug-resistant versus parental human melanoma cell lines. Anticancer Res 2006; 26:2137-42; PMID:16827156.
   PubMed Web of Science ®Google Scholar
• Svane IM, Verdegaal EM. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? Cancer Immunol Immunother 2014; 63:1081-91; PMID:25099366; http://dx.doi.org/10.1007/s00262-014-1580-5.
   PubMed Web of Science ®Google Scholar
• Slingluff CL, Jr., Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother 2000; 48:661-72; PMID:10752474; http://dx.doi.org/10.1007/s002620050015.
   PubMed Web of Science ®Google Scholar
• Marchand M, Brichard V, van Baren N, Coulie PG. Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther 2001; 1:497-510; PMID:11727521; http://dx.doi.org/10.1517/14712598.1.3.497.
   PubMed Web of Science ®Google Scholar
• Kaluza KM, Thompson JM, Kottke TJ, Flynn Gilmer HC, Knutson DL, Vile RG. Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants. Int J Cancer 2012; 131:844-54; PMID:21935923; http://dx.doi.org/10.1002/ijc.26447.
   PubMed Web of Science ®Google Scholar
• Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wolfel T, Holzel M et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490:412-6; PMID:23051752; http://dx.doi.org/10.1038/nature11538.
   PubMed Web of Science ®Google Scholar
• Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol 2006; 176:3374-82; PMID:16517705; http://dx.doi.org/10.4049/jimmunol.176.6.3374.
   PubMed Web of Science ®Google Scholar
• Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, Real LM, Garrido F, Cabrera T. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008; 60:439-47; PMID:18545995; http://dx.doi.org/10.1007/s00251-008-0303-5.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65:333-47; PMID:24274181; http://dx.doi.org/10.1146/annurev-med-060512-150254.
   PubMed Web of Science ®Google Scholar
• Hart DP, Xue SA, Thomas S, Cesco-Gaspere M, Tranter A, Willcox B, Lee SP, Steven N, Morris EC, Stauss HJ. Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. Gene Ther 2008; 15:625-31; PMID:18305579; http://dx.doi.org/10.1038/sj.gt.3303078.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 2013; 24:717-27; PMID:23883116; http://dx.doi.org/10.1089/hum.2013.075.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010; 70:9053-61; PMID:20926399; http://dx.doi.org/10.1158/0008-5472.CAN-10-2880.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM et al. Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies. Cancer Immunol Res 2014; 2:112-20; PMID:24579088; http://dx.doi.org/10.1158/2326-6066.CIR-13-0170.
   PubMed Web of Science ®Google Scholar
• Schaft N, Dorrie J, Thumann P, Beck VE, Muller I, Schultz ES, Kampgen E, Dieckmann D, Schuler G. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 2005; 174:3087-97; PMID:15728524; http://dx.doi.org/10.4049/jimmunol.174.5.3087.
   PubMed Web of Science ®Google Scholar
• Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der BP, Thielemans K. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004; 172:6649-57; PMID:15153480; http://dx.doi.org/10.4049/jimmunol.172.11.6649.
   PubMed Web of Science ®Google Scholar